Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 707-712

  Zheng, Changcheng ^a   Luan, Zuo ^b   Fang, Jianpei ^c   Sun, Xin ^d   Chen, Jing ^e   Li, Chi Kong ^f   Hu, Shaoyan ^g   Zhu, Yiping ^h   Sun, Zimin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^h SICHUAN UNIVERSITY   (China)

Author keywords

Antithymocyte globulin; Children; Cord blood transplantation; Hematological malignancies

Indexed keywords

HLA ANTIGEN; THYMOCYTE ANTIBODY; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIBODY;

ARTICLE; CHILD; CHILDHOOD MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEUTROPHIL; OVERALL SURVIVAL; PRESCHOOL CHILD; RECURRENCE FREE SURVIVAL; SURGICAL MORTALITY; T CELL DEPLETION; ADOLESCENT; ALLOGRAFT; CLINICAL TRIAL; COMPARATIVE STUDY; HEMATOLOGIC NEOPLASMS; INFANT; MORTALITY; MULTICENTER STUDY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ALLOGRAFTS; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84924298470     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.023     Document Type: Article

References (28)

1. Atta E.H., de Oliveira D.C., Bouzas L.F., et al. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation. PLoS One 2014, 9:e107155.
2. Devillier R., Fürst S., Crocchiolo R., et al. Aconditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Am J Hematol 2014, 89:83-87.
3. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391.
4. Kröger N., Zabelina T., Binder T., et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 2009, 15:454-462.
5. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
6. Chen Y.H., Xu L.P., Liu D.H., et al. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis. Chin Med J (Engl) 2013, 126:2499-2503.
7. Atsuta Y., Morishima Y., Suzuki R., et al. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Biol Blood Marrow Transplant 2012, 18:780-787.
8. Takahashi S., Ooi J., Tomonari A., et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007, 109:1322-1330.
9. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. NEngl J Med 2004, 351:2276-2285.
10. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
11. Merindol N., Charrier E., Duval M., Soudeyns H. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. JLeukoc Biol 2011, 90:49-60.
12. Zheng C., Zhu X., Tang B., et al. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia. Ann Hematol 2015, 94:473-480.
13. Dignan F.L., Clark A., Amrolia P., et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012, 158:30-45.
14. Dignan F.L., Amrolia P., Clark A., et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012, 158:46-61.
15. Kumar A., Mhaskar A.R., Reljic T., et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012, 26:582-588.
16. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
17. Lindemans C.A., Chiesa R., Amrolia P.J., et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014, 123:126-132.
18. Granata A., Castagna L., Crocchiolo R., et al. Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation. Exp Hematol 2013, 41:503-505.
19. Nakamae H., Storer B., Sandmaier B.M., et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011, 96:1838-1845.
20. Kuwatsuka Y., Atsuta Y., Horowitz M.M., et al. Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations. Biol Blood Marrow Transplant 2014, 20:662-667.
21. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004, 104:3813-3820.
22. Hagen P., Wagner J.E., DeFor T.E., et al. The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. Bone Marrow Transplant 2014, 49:1498-1504.
23. Ostronoff F., Milano F., Gooley T., et al. Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin. Bone Marrow Transplant 2013, 48:782-786.
24. Schaenman J.M., Shashidhar S., Rhee C., et al. Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol Blood Marrow Transplant 2011, 17:693-702.
25. Sauter C., Abboud M., Jia X., et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011, 17:1460-1471.
26. Du K., Hu Y., Wu K., Huang H. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transplant 2013, 27:E91-E100.
27. Remberger M., Ringdén O., Hägglund H., et al. Ahigh antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant 2013, 27:E368-E374.
28. Remberger M., Mattsson J., Svahn B.M., Ringdén O. Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose. Bone Marrow Transplant 2008, 42:769-771.